{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:38:11Z","timestamp":1792791491338,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009252","name":"SciLifeLab","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["807015"],"award-info":[{"award-number":["807015"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["821528"],"award-info":[{"award-number":["821528"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2018-03310"],"award-info":[{"award-number":["2018-03310"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2021-03293"],"award-info":[{"award-number":["2021-03293"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-04198"],"award-info":[{"award-number":["2022-04198"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004722","name":"Lars Hierta Memorial Foundation","doi-asserted-by":"publisher","award":["FO2023-0227"],"award-info":[{"award-number":["FO2023-0227"]}],"id":[{"id":"10.13039\/501100004722","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["FO2023-0241"],"award-info":[{"award-number":["FO2023-0241"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["FO2025-0323-HK-250"],"award-info":[{"award-number":["FO2025-0323-HK-250"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["FO2021-0318"],"award-info":[{"award-number":["FO2021-0318"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020098","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001725","name":"Royal Swedish Academy of Sciences","doi-asserted-by":"publisher","award":["ME2024-0048"],"award-info":[{"award-number":["ME2024-0048"]}],"id":[{"id":"10.13039\/501100001725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.neurot.2026.e01101","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:34:15Z","timestamp":1792661655000},"page":"e01101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Spatial pharmacometabolomic profiling of two antipsychotics reveals region-specific neurochemical alterations in the rat brain"],"prefix":"10.1016","volume":"24","author":[{"given":"Yea-Rin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivetha","family":"Dayanidhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Loryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareta","family":"Hammarlund-Udenaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Shariatgorji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per E.","family":"Andr\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodosia","family":"Vallianatou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neurot.2026.e01101_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1176\/ajp.135.2.164","article-title":"Antipsychotic drugs, neurotransmitters, and schizophrenia","volume":"135","author":"Carlsson","year":"1978","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01101_bib2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/BF00431935","article-title":"Oral dyskinesia in rats following brain lesions and neuroleptic drug administration","volume":"77","author":"Gunne","year":"1982","journal-title":"Psychopharmacology (Berl)"},{"issue":"5966","key":"10.1016\/j.neurot.2026.e01101_bib3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/309347a0","article-title":"Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis","volume":"309","author":"Gunne","year":"1984","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01101_bib4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/00002826-199302000-00012","article-title":"An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia","volume":"16","author":"Gunne","year":"1993","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01101_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd2806","article-title":"The 'atypicality' of antipsychotics: a concept re-examined and re-defined","volume":"8","author":"Gr\u00fcnder","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01101_bib6","doi-asserted-by":"crossref","DOI":"10.4103\/AMH.AMH_4_20","article-title":"A comparative study on metabolic syndrome in patients with schizophrenia treated using first-generation and second-generation antipsychotics","volume":"21","author":"Panati","year":"2020","journal-title":"Archives of Mental Health"},{"key":"10.1016\/j.neurot.2026.e01101_bib7","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00406-021-01335-y","article-title":"Should 'typical', first-generation antipsychotics no longer be generally used in the treatment of schizophrenia?","volume":"271","author":"Leucht","year":"2021","journal-title":"Eur Arch Psychiatr Clin Neurosci"},{"key":"10.1016\/j.neurot.2026.e01101_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110296","article-title":"Neuropharmacological effect of risperidone: from chemistry to medicine","volume":"369","author":"Bhat","year":"2023","journal-title":"Chem Biol Interact"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01101_bib9","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jpba.2010.03.040","article-title":"Liquid chromatography\/tandem mass spectrometry method for determination of olanzapine and N-desmethylolanzapine in human serum and cerebrospinal fluid","volume":"53","author":"Josefsson","year":"2010","journal-title":"J Pharm Biomed Anal"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01101_bib10","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1592\/phco.24.17.1759.52346","article-title":"Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis","volume":"24","author":"Jann","year":"2004","journal-title":"Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01101_bib11","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.1006e13","article-title":"Cognitive and functional effects of atypical antipsychotic medications","volume":"67","author":"Harvey","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01101_bib12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/bcp.12927","article-title":"The antipsychotic story: changes in prescriptions and overdose without better safety","volume":"82","author":"Berling","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01101_bib13","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01101_bib14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41386-025-02060-z","article-title":"A molecular mechanism mediating clozapine-enhanced sensorimotor gating","volume":"50","author":"Mantas","year":"2025","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01101_bib15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/archgenpsychiatry.2010.199","article-title":"Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia","volume":"68","author":"Ho","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 2","key":"10.1016\/j.neurot.2026.e01101_bib16","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1007\/s00406-012-0360-5","article-title":"Multimodal functional and structural imaging investigations in psychosis research","volume":"262","author":"Schultz","year":"2012","journal-title":"Eur Arch Psychiatr Clin Neurosci"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01101_bib17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1001\/jamapsychiatry.2014.2178","article-title":"A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia","volume":"72","author":"Lesh","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01101_bib18","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/npp.2013.288","article-title":"White matter changes associated with antipsychotic treatment in first-episode psychosis","volume":"39","author":"Szeszko","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01101_bib19","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/archpsyc.62.4.361","article-title":"Antipsychotic drug effects on brain morphology in first-episode psychosis","volume":"62","author":"Lieberman","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01101_bib20","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jamapsychiatry.2020.0036","article-title":"Effects of antipsychotic medication on brain structure in patients with major depressive disorder and psychotic features: neuroimaging findings in the context of a randomized placebo-controlled clinical trial","volume":"77","author":"Voineskos","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01101_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000100981","article-title":"Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation","volume":"85","author":"Tulipano","year":"2007","journal-title":"Neuroendocrinology"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01101_bib22","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0278-5846(02)00208-7","article-title":"The hypothalamic-pituitary-adrenal axis in chronic schizophrenic patients long-term treated with neuroleptics","volume":"26","author":"Kaneda","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01101_bib23","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0306-4522(03)00105-2","article-title":"Chronic stress attenuates glucocorticoid negative feedback: involvement of the prefrontal cortex and hippocampus","volume":"119","author":"Mizoguchi","year":"2003","journal-title":"Neuroscience"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01101_bib24","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/jms.3888","article-title":"Trypsin and MALDI matrix pre-coated targets simplify sample preparation for mapping proteomic distributions within biological tissues by imaging mass spectrometry","volume":"51","author":"Zubair","year":"2016","journal-title":"J Mass Spectrom"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01101_bib25","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/schbul\/sbv125","article-title":"A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-Month outcomes","volume":"41","author":"Robinson","year":"2015","journal-title":"Schizophr Bull"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01101_bib26","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jamapsychiatry.2018.1088","article-title":"Metabolic effects of antipsychotics on adiposity and insulin sensitivity in youths: a randomized clinical trial","volume":"75","author":"Nicol","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01101_bib27","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.2337\/db10-0449","article-title":"Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance","volume":"59","author":"Martins","year":"2010","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01101_bib28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41398-023-02686-x","article-title":"Olanzapine, risperidone and ziprasidone differently affect lysosomal function and autophagy, reflecting their different metabolic risk in patients","volume":"14","author":"Pozzi","year":"2024","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.neurot.2026.e01101_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.711940","article-title":"Genetic polymorphisms associated with the pharmacokinetics, pharmacodynamics and adverse effects of olanzapine, aripiprazole and risperidone","volume":"12","author":"Soria-Chacartegui","year":"2021","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01101_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe5948","article-title":"Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia","volume":"7","author":"Fridjonsdottir","year":"2021","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01101_bib31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41531-022-00299-7","article-title":"Basal ganglia neuropeptides show abnormal processing associated with L-DOPA-induced dyskinesia","volume":"8","author":"Hulme","year":"2022","journal-title":"npj Parkinson's Dis"},{"issue":"15","key":"10.1016\/j.neurot.2026.e01101_bib32","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1021\/acschemneuro.4c00199","article-title":"Applying spatial metabolomics to investigate Age- and drug-induced neurochemical changes","volume":"15","author":"Vallianatou","year":"2024","journal-title":"ACS Chem Neurosci"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01101_bib33","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/s41592-019-0551-3","article-title":"Comprehensive mapping of neurotransmitter networks by MALDI-MS imaging","volume":"16","author":"Shariatgorji","year":"2019","journal-title":"Nat Methods"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01101_bib34","doi-asserted-by":"crossref","first-page":"7732","DOI":"10.1038\/s41380-021-01267-y","article-title":"Neuropharmacokinetic visualization of regional and subregional unbound antipsychotic drug transport across the blood-brain barrier","volume":"26","author":"Lupt\u00e1kov\u00e1","year":"2021","journal-title":"Mol Psychiatr"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01101_bib35","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/mp.2015.229","article-title":"In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy","volume":"21","author":"Loryan","year":"2016","journal-title":"Mol Psychiatr"},{"key":"10.1016\/j.neurot.2026.e01101_bib36","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2005"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01101_bib37","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1021\/acs.analchem.4c05665","article-title":"Comprehensive approach for sequential MALDI-MSI analysis of lipids, N-Glycans, and peptides in fresh-frozen rodent brain tissues","volume":"97","author":"Lee","year":"2025","journal-title":"Anal Chem"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01101_bib38","article-title":"Derivatization of small molecules using deuterated analog of reactive matrix to facilitate identification in mass spectrometry imaging","volume":"5","author":"Vallianatou","year":"2025","journal-title":"Chem Mater"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01101_bib39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1021\/acschembio.1c00803","article-title":"Region-Specific and age-dependent multitarget effects of acetylcholinesterase inhibitor tacrine on comprehensive neurotransmitter systems","volume":"17","author":"Fridjonsdottir","year":"2022","journal-title":"ACS Chem Biol"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01101_bib40","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/s41592-019-0551-3","article-title":"Comprehensive mapping of neurotransmitter networks by MALDI-MS imaging","volume":"16","author":"Shariatgorji","year":"2019","journal-title":"Nat Methods"},{"issue":"50","key":"10.1016\/j.neurot.2026.e01101_bib41","doi-asserted-by":"crossref","first-page":"18352","DOI":"10.1021\/acs.analchem.3c02900","article-title":"Rapid metabolic profiling of 1 \u03bcL crude cerebrospinal fluid by matrix-assisted laser Desorption\/Ionization mass spectrometry imaging can differentiate","volume":"95","author":"Vallianatou","year":"2023","journal-title":"Anal Chem"},{"issue":"16","key":"10.1016\/j.neurot.2026.e01101_bib42","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.1021\/acs.analchem.5c00633","article-title":"Met-ID: an open-source software for Comprehensive Annotation of Multiple On-Tissue Chemical Modifications in MALDI-MSI","volume":"97","author":"Bj\u00e4rterot","year":"2025","journal-title":"Anal Chem"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01101_bib43","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1021\/ac9026115","article-title":"Structural characterization of phospholipids and peptides directly from tissue sections by MALDI traveling-wave ion mobility-mass spectrometry","volume":"82","author":"Ridenour","year":"2010","journal-title":"Anal Chem"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01101_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.202100223","article-title":"An optimized MALDI MSI protocol for spatial detection of tryptic peptides in fresh frozen prostate tissue","volume":"22","author":"H\u00f8iem","year":"2022","journal-title":"Proteomics"},{"issue":"14","key":"10.1016\/j.neurot.2026.e01101_bib45","doi-asserted-by":"crossref","first-page":"7672","DOI":"10.1021\/acs.analchem.4c04818","article-title":"Optimization of collagenase proteomics for improved mass spectrometry imaging peptide identification","volume":"97","author":"Macdonald","year":"2025","journal-title":"Anal Chem"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01101_bib46","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1021\/acs.analchem.7b04733","article-title":"Mass spectrometry imaging: a review of emerging advancements and future insights","volume":"90","author":"Buchberger","year":"2018","journal-title":"Anal Chem"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01101_bib47","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/PL00005334","article-title":"Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4","volume":"359","author":"Fang","year":"1999","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"2 Suppl","key":"10.1016\/j.neurot.2026.e01101_bib48","doi-asserted-by":"crossref","first-page":"106s","DOI":"10.1038\/sj.npp.1395370","article-title":"The role of serotonin in antipsychotic drug action","volume":"21","author":"Meltzer","year":"1999","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01101_bib49","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.neuron.2016.03.011","article-title":"Glycolytic enzymes localize to synapses under energy stress to support synaptic function","volume":"90","author":"Jang","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2026.e01101_bib50","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fncel.2019.00363","article-title":"Brain-Derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain","volume":"13","author":"Miranda","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.neurot.2026.e01101_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.1038614","article-title":"Synapse integrity and function: dependence on protein synthesis and identification of potential failure points","volume":"15","author":"Cohen","year":"2022","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.neurot.2026.e01101_bib52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuroscience.2014.01.025","article-title":"The role of D2-autoreceptors in regulating dopamine neuron activity and transmission","volume":"282","author":"Ford","year":"2014","journal-title":"Neuroscience"},{"issue":"1-2","key":"10.1016\/j.neurot.2026.e01101_bib53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01101_bib54","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/sj.npp.1301242","article-title":"Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia","volume":"32","author":"Agid","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01101_bib55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0925-4927(99)00032-3","article-title":"Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia","volume":"92","author":"Lavalaye","year":"1999","journal-title":"Psychiatry Res"},{"issue":"43","key":"10.1016\/j.neurot.2026.e01101_bib56","doi-asserted-by":"crossref","first-page":"13730","DOI":"10.1523\/JNEUROSCI.4172-09.2009","article-title":"Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission?","volume":"29","author":"Ito","year":"2009","journal-title":"J Neurosci"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01101_bib57","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/sj.bjp.0705396","article-title":"Differences in the mechanisms that increase noradrenaline efflux after administration of d-amphetamine: a dual-probe microdialysis study in rat frontal cortex and hypothalamus","volume":"139","author":"G\u00e9ranton","year":"2003","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01101_bib58","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0893-133X(02)00314-7","article-title":"Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia: a comparison with clozapine and placebo","volume":"27","author":"Elman","year":"2002","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.neurot.2026.e01101_bib62","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/sj.npp.1300460","article-title":"Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents","volume":"29","author":"Ugale","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"2-3","key":"10.1016\/j.neurot.2026.e01101_bib63","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.schres.2014.10.034","article-title":"Olanzapine antipsychotic treatment of adolescent rats causes long term changes in glutamate and GABA levels in the nucleus accumbens","volume":"161","author":"Xu","year":"2015","journal-title":"Schizophr Res"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01101_bib64","doi-asserted-by":"crossref","first-page":"9431","DOI":"10.3390\/ijms16059431","article-title":"Nucleotide salvage deficiencies, DNA damage and neurodegeneration","volume":"16","author":"Fasullo","year":"2015","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01101_bib65","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1471-4159.2001.00607.x","article-title":"Adenosine in the central nervous system: release mechanisms and extracellular concentrations","volume":"79","author":"Latini","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.neurot.2026.e01101_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1257460","article-title":"Second-generation antipsychotics and metabolic syndrome: a role for mitochondria","volume":"14","author":"Mortimer","year":"2023","journal-title":"Front Psychiatr"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01101_bib68","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/s42255-023-00863-2","article-title":"The pentose phosphate pathway in health and disease","volume":"5","author":"TeSlaa","year":"2023","journal-title":"Nat Metab"},{"key":"10.1016\/j.neurot.2026.e01101_bib69","article-title":"Plasma lysophosphatidylcholine and lysophosphatidylethanolamine levels were associated with the therapeutic response to olanzapine in female antipsychotics-na\u00efve first-episode patients with schizophrenia","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01101_bib70","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s12272-013-0105-7","article-title":"Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia","volume":"36","author":"Park","year":"2013","journal-title":"Arch Pharm Res (Seoul)"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01101_bib71","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/YIC.0000000000000040","article-title":"Pharmacokinetics of olanzapine long-acting injection: the clinical perspective","volume":"29","author":"Heres","year":"2014","journal-title":"Int Clin Psychopharmacol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:46:35Z","timestamp":1792788395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926002710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2027,1]]}},"alternative-id":["S1878747926002710"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01101","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spatial pharmacometabolomic profiling of two antipsychotics reveals region-specific neurochemical alterations in the rat brain","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e01101"}}